Jul 17, 2026 05:17AM
Jun 17, 2026 08:45AM
Jun 17, 2026 08:45AM
May 5, 2026 07:22AM
May 5, 2026 07:00AM
Apr 29, 2026 07:00AM
Apr 29, 2026 07:00AM Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
Apr 28, 2026 07:00AM
Apr 13, 2026 07:01AM
Apr 13, 2026 07:00AM
Feb 17, 2026 07:02AM
Feb 17, 2026 07:00AM
Feb 5, 2026 07:43AM
Feb 5, 2026 07:00AM Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Jan 21, 2026 07:00AM
Jan 21, 2026 07:00AM
Dec 8, 2025 07:02AM
Dec 8, 2025 07:00AM
Nov 24, 2025 07:00AM
Nov 24, 2025 07:00AM
Nov 4, 2025 07:12AM Ocular Therapeutix (OCUL) Misses Q3 EPS by 1c
Nov 4, 2025 07:05AM
Nov 4, 2025 07:02AM
Nov 4, 2025 07:00AM
Oct 28, 2025 07:00AM
Sep 30, 2025 06:21AM
Sep 30, 2025 06:21AM
Aug 12, 2025 07:01AM Ocular Therapeutix gets FDA agreement for AXPAXLI diabetic eye trial
Aug 12, 2025 07:00AM
Aug 5, 2025 11:11AM
Aug 5, 2025 11:07AM
Aug 5, 2025 07:13AM
Aug 5, 2025 07:00AM
Jul 29, 2025 07:00AM
May 5, 2025 07:04AM Ocular Therapeutix (OCUL) Misses Q1 EPS by 9c
May 5, 2025 07:00AM
Apr 28, 2025 07:00AM
Mar 4, 2025 06:42AM
Mar 3, 2025 07:10AM
Mar 3, 2025 07:00AM
Feb 24, 2025 07:00AM
Jan 14, 2025 07:03AM Ocular Therapeutix (OCUL) Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI in NPDR
Jan 14, 2025 07:00AM
Dec 2, 2024 07:30AM
Nov 15, 2024 06:51AM
Nov 14, 2024 07:04AM
Nov 14, 2024 07:00AM
Nov 12, 2024 07:31AM
Nov 12, 2024 07:30AM Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
Nov 6, 2024 07:30AM

1,205,326 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All